Characteristics | Total | No. patients (%) | P | |
---|---|---|---|---|
CTC HER2+ | CTC HER2- | |||
Overall | 58 | 22 (37.9) | 36 (62.1) | Â |
Age (years) | Â | Â | Â | Â |
 Median | 48.5 | 49.0 | 46.5 | 0.289 |
 Range | 27–68 | 29–68 | 27–65 | |
ER and/or PR | Â | Â | Â | Â |
 Positive | 33 | 8 (24.2) | 25 (75.8) | 0.014 |
 Negative | 25 | 14 (56.0) | 11 (44.0) | |
No. of Metastasis | Â | Â | Â | Â |
 1 | 8 | 5 (62.5) | 3 (37.5) | 0.238 |
 ≥ 2 | 50 | 17 (34.0) | 33 (66.0) | |
Metastatic sites | Â | Â | Â | Â |
 Visceral | 44 | 16 (36.4) | 28 (63.6) | 0.663 |
 Non-visceral | 14 | 6 (42.9) | 8 (57.1) | |
DFS | Â | Â | Â | Â |
 ≤ 12 | 24 | 12 (50.0) | 12 (50.0) | 0.111 |
 > 12 | 34 | 10 (29.4) | 24 (70.6) | |
Systemic therapy line | Â | Â | Â | Â |
 1 | 7 | 5 (71.4) | 2 (28.6) | 0.092 |
 ≥ 2 | 51 | 17 (33.3) | 34 (66.7) | |
Treatment option | Â | Â | Â | Â |
 Trastuzumab + Chemo | 43 | 19 (44.2) | 24 (55.8) | 0.096 |
 Lapatinib + Chemo | 15 | 3 (20.0) | 12 (80.0) |